Biohaven (BHVN) Competitors

$9.08 +0.05 (+0.53%)

Closing price 05/14/2026 03:59 PM Eastern

Extended Trading

$9.01 -0.07 (-0.75%)

As of 08:13 AM Eastern

BHVN vs. COGT, CNTA, IMVT, SRRK, and GRFS

Should you buy Biohaven stock or one of its competitors? MarketBeat compares Biohaven with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biohaven include Cogent Biosciences (COGT), Centessa Pharmaceuticals (CNTA), Immunovant (IMVT), Scholar Rock (SRRK), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Biohaven compare to Cogent Biosciences?

Biohaven (NYSE:BHVN) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Biohaven has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

In the previous week, Biohaven had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.84 beat Biohaven's score of 0.34 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven currently has a consensus target price of $22.27, indicating a potential upside of 145.28%. Cogent Biosciences has a consensus target price of $43.73, indicating a potential upside of 27.89%. Given Biohaven's higher possible upside, analysts plainly believe Biohaven is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

88.8% of Biohaven shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cogent Biosciences' return on equity of -104.27% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Biohaven and Cogent Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Biohaven compare to Centessa Pharmaceuticals?

Biohaven (NYSE:BHVN) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Biohaven has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for Centessa Pharmaceuticals and 4 mentions for Biohaven. Centessa Pharmaceuticals' average media sentiment score of 0.41 beat Biohaven's score of 0.34 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biohaven currently has a consensus target price of $22.27, indicating a potential upside of 145.28%. Centessa Pharmaceuticals has a consensus target price of $40.70, indicating a potential upside of 2.78%. Given Biohaven's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biohaven is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Centessa Pharmaceuticals' return on equity of -60.37% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Summary

Biohaven beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Biohaven compare to Immunovant?

Biohaven (NYSE:BHVN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Biohaven has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Biohaven and Biohaven both had 4 articles in the media. Immunovant's average media sentiment score of 0.89 beat Biohaven's score of 0.34 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven currently has a consensus target price of $22.27, indicating a potential upside of 145.28%. Immunovant has a consensus target price of $32.44, indicating a potential upside of 12.03%. Given Biohaven's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biohaven is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Immunovant is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunovant's return on equity of -63.17% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Immunovant	N/A	-63.17%	-58.01%

Summary

Biohaven beats Immunovant on 8 of the 13 factors compared between the two stocks.

How does Biohaven compare to Scholar Rock?

Biohaven (NYSE:BHVN) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scholar Rock's return on equity of -163.52% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Scholar Rock	N/A	-163.52%	-96.67%

Biohaven has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

In the previous week, Scholar Rock had 18 more articles in the media than Biohaven. MarketBeat recorded 22 mentions for Scholar Rock and 4 mentions for Biohaven. Scholar Rock's average media sentiment score of 0.87 beat Biohaven's score of 0.34 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Biohaven currently has a consensus target price of $22.27, indicating a potential upside of 145.28%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 9.20%. Given Biohaven's higher possible upside, research analysts clearly believe Biohaven is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	5 Strong Buy rating(s)	3.17

Summary

Scholar Rock beats Biohaven on 10 of the 14 factors compared between the two stocks.

How does Biohaven compare to Grifols?

Biohaven (NYSE:BHVN) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

88.8% of Biohaven shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Grifols has a net margin of 5.54% compared to Biohaven's net margin of 0.00%. Grifols' return on equity of 6.21% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Grifols	5.54%	6.21%	2.39%

Biohaven has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Grifols has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

In the previous week, Biohaven and Biohaven both had 4 articles in the media. Grifols' average media sentiment score of 1.16 beat Biohaven's score of 0.34 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Grifols	$8.51B	0.62	$454.82M	$0.19	41.00

Biohaven currently has a consensus target price of $22.27, indicating a potential upside of 145.28%. Grifols has a consensus target price of $10.00, indicating a potential upside of 28.37%. Given Biohaven's stronger consensus rating and higher possible upside, research analysts clearly believe Biohaven is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Grifols beats Biohaven on 8 of the 15 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.36B	$3.42B	$6.34B	$22.90B
Dividend Yield	N/A	2.31%	2.80%	4.09%
P/E Ratio	-1.60	18.47	20.66	30.78
Price / Sales	N/A	294.84	542.63	95.02
Price / Cash	N/A	125.29	43.26	25.31
Price / Book	10.56	6.93	9.93	4.67
Net Income	-$738.82M	$24.11M	$3.55B	$1.06B
7 Day Performance	-7.63%	5.89%	1.70%	-0.89%
1 Month Performance	-12.25%	-0.91%	0.49%	1.42%
1 Year Performance	-42.58%	74.58%	39.41%	24.64%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	2.3969 of 5 stars	$9.08 +0.5%	$22.27 +145.3%	-53.5%	$1.36B	N/A	N/A	239	Analyst Forecast
COGT Cogent Biosciences	3.12 of 5 stars	$34.10 -1.8%	$43.73 +28.2%	+600.6%	$5.94B	N/A	N/A	80
CNTA Centessa Pharmaceuticals	2.0989 of 5 stars	$39.59 flat	$40.70 +2.8%	+222.7%	$5.91B	N/A	N/A	200
IMVT Immunovant	1.9371 of 5 stars	$29.06 +0.4%	$32.44 +11.6%	+110.2%	$5.89B	N/A	N/A	120
SRRK Scholar Rock	2.0163 of 5 stars	$48.35 -0.1%	$56.00 +15.8%	+67.9%	$5.80B	N/A	N/A	140	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors

BHVN vs. COGT, CNTA, IMVT, SRRK, and GRFS

How does Biohaven compare to Cogent Biosciences?

Summary

How does Biohaven compare to Centessa Pharmaceuticals?

Summary

How does Biohaven compare to Immunovant?

Summary

How does Biohaven compare to Scholar Rock?

Summary

How does Biohaven compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biohaven (BHVN) Competitors

BHVN vs. COGT, CNTA, IMVT, SRRK, and GRFS

How does Biohaven compare to Cogent Biosciences?

Which has more volatility and risk, BHVN or COGT?

Does the media prefer BHVN or COGT?

Do analysts prefer BHVN or COGT?

Which has higher valuation and earnings, BHVN or COGT?

Do institutionals & insiders believe in BHVN or COGT?

Is BHVN or COGT more profitable?

Summary

How does Biohaven compare to Centessa Pharmaceuticals?

Which has more risk and volatility, BHVN or CNTA?

Does the media prefer BHVN or CNTA?

Do analysts rate BHVN or CNTA?

Which has better earnings and valuation, BHVN or CNTA?

Do institutionals & insiders believe in BHVN or CNTA?

Is BHVN or CNTA more profitable?

Summary

How does Biohaven compare to Immunovant?

Which has more risk and volatility, BHVN or IMVT?

Does the media prefer BHVN or IMVT?

Do analysts rate BHVN or IMVT?

Which has better earnings and valuation, BHVN or IMVT?

Do institutionals & insiders believe in BHVN or IMVT?

Is BHVN or IMVT more profitable?

Summary

How does Biohaven compare to Scholar Rock?

Do insiders and institutionals believe in BHVN or SRRK?

Is BHVN or SRRK more profitable?

Which has more risk & volatility, BHVN or SRRK?

Does the media prefer BHVN or SRRK?

Which has preferable earnings & valuation, BHVN or SRRK?

Do analysts rate BHVN or SRRK?

Summary

How does Biohaven compare to Grifols?

Do insiders and institutionals believe in BHVN or GRFS?

Is BHVN or GRFS more profitable?

Which has more risk & volatility, BHVN or GRFS?

Does the media prefer BHVN or GRFS?

Which has preferable earnings & valuation, BHVN or GRFS?

Do analysts rate BHVN or GRFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools